NeutriSci International Inc. ('NeutriSci' or the 'Company') (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy announces that it intends to consolidate its common shares ('Common Shares') on a ten (10) old for one (1) new basis (the 'Consolidation').

The Consolidation will reduce the number of outstanding Common Shares from 120,698,600 to approximately 12,069,860. No fractional Common Shares will be issued pursuant to the Consolidation and any fractional Common Shares that would otherwise be issued shall be rounded to the nearest whole number.

The Company's articles of incorporation authorize the Company's board of directors to approve certain changes to the Company's capital structure, including the Consolidation. As such, shareholder approval for the Consolidation is not required. The Company will issue a further news release indicating the effective date of the Consolidation and the date on which the Company's shares will commence trading on a post-Consolidation basis. The name of the Company and its trading symbol will not be changed as a result of the Consolidation. The Company further announces that it will not be proceeding with the proposed financing as announced on October 28, 2019. The Company now proposes to complete a non-brokered private placement offering (the 'Offering'), on a post-Consolidation basis, to raise up to $500,000 through the issuance of up to 2,500,000 post-Consolidation units (the 'Units') at a price of $0.20 per Unit. Each Unit will consist of one post-Consolidated common share and one share purchase warrant, with each share purchase warrant entitling the holder to acquire one additional post-Consolidated common share at a price of $0.25 per share for a period of 24 months from the date the warrants are issued. The Company may pay a finder's fee to one or more arms' length parties who introduce the Company to eligible subscribers, in accordance with the policies of the TSX Venture Exchange. Glen Rehman, CEO of NeutriSci, stated: 'As we continue to focus on the launch of our products through our manufacturing and distribution partnerships in the US, South America and with ANB Canada in Canada, it is management's opinion that the Company's existing issued and outstanding share capital is not conducive to completing additional equity financing and that the Consolidation is required in order to attract new equity investment in the Company.' Net proceeds of the Offering will be used for marketing programs, production runs, and for general corporate purposes. All securities to be issued in connection with the Offering will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Completion of the Consolidation and the Offering remains subject to the approval of the TSX Venture Exchange. Completion of the Offering is subject to completion of the Consolidation.

Contact:

Tel: (403) 264-6320

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy, the Company's natural energy and focus supplement that has at its core, the beneficial effects of blueberries. Neuenergy contains a unique patented combination of blueberry extract (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products.

(C) 2019 Electronic News Publishing, source ENP Newswire